News

January 5, 2018

Cure SMA Launches Advocacy Action Network

Cure SMA Launches Advocacy Action Network

Working together, we’ve achieved tremendous success in advocating for ourselves, our families, and our whole community, particularly in the past few years.

Today, we’re building on this momentum with the launch of our

READ MORE   |  

Topics: Our Impact, Advocacy, Front Page News

January 4, 2018

Minnesota Becomes Second State to Adopt Newborn Screening for SMA

On December 27, the Minnesota Commissioner of Health accepted the recommendation of the state's Advisory Committee on Heritable and Congenital Disorders to add SMA to Minnesota’s newborn screening panel. With this decision, Minnesota becomes the second state, after Missouri, to adopt permanent newborn screening for SMA.

Cure SMA...

READ MORE   |  

Topics: Our Impact, Advocacy, Front Page News

January 3, 2018

Cure SMA Announces Funding for Care Centers Across the US

Cure SMA is pleased to announce the first grants from $450,000 in funding to help increase capacity at SMA treatment sites across the US.

In order to increase the number of affected individuals that sites can follow, treat and evaluate, Cure SMA will award $50,000 grants to nine sites, for a total of $450,000 in funding. These grants...

READ MORE   |  

Topics: Support & Care, Research, Front Page News

December 29, 2017

Biogen and Ionis Enter Into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy

Biogen and Ionis Pharmaceuticals announced that they have entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of spinal...

READ MORE   |  

Topics: Our Impact, Research, Front Page News

December 27, 2017

Cure SMA Assists Hundreds of Families in 2017

Cure SMA Assists Hundreds of Families in 2017

Each year, Cure SMA provides thousands of families with vital support and resources to help them live active, engaged and hopeful lives.

Our programs provide tangible support for families affected by SMA, easing the difficulties of an SMA diagnosis, and showing each family that they...

READ MORE   |  

Topics: Support & Care, Our Impact, Front Page News

December 22, 2017

Miller McNeil Woodruff Foundation Awards Cure SMA Generous Gift

Miller McNeil Woodruff Foundation Awards Cure SMA Generous Gift

The Miller McNeil Woodruff Foundation recently awarded $87,000 to Cure SMA, in order to further research that will lead to treatments for all ages, stages and types of SMA. Their gift will also help fund continued advocacy and awareness initiatives.

The generous donation is made each...

READ MORE   |  

Topics: Community & Awareness, Support & Care, Front Page News

December 21, 2017

Fall 2017 Directions Now Available for Download

Fall 2017 Directions Now Available for Download

The Fall 2017 issue of Directions is now available. Please visit our Support & Care Publications page to download this issue or past...

READ MORE   |  

Topics: Community & Awareness, Support & Care, Front Page News

December 19, 2017

2017 Research Year-in-Review

Over our past fiscal year—from July 1, 2016, to June 30, 2017—Cure SMA has funded 28 projects with over $2.5 million in new research funding. This funding will be used strategically to help accelerate research, and ensure we are developing treatments for all types, ages, and stages of SMA. The areas funded...

READ MORE   |  

Topics: Our Impact, Research, Front Page News

December 18, 2017

Cure SMA Advocates Continue to Advance Newborn Screening Efforts

Cure SMA Advocates Continue to Advance Newborn Screening Efforts

SMA advocates across the country are working tirelessly with Cure SMA to educate state decision makers on newborn screening. In Maryland and Minnesota, the states’ Newborn Screening Advisory Committees voted to approve a recommendation to add SMA to the state panel. We now await final...

READ MORE   |  

Topics: Community & Awareness, Advocacy, Front Page News

December 13, 2017

AveXis Announces Plan to Initiate Phase 1 Trial in SMA Type 2 Utilizing Intrathecal Delivery of AVXS-101

AveXis Announces Plan to Initiate Phase 1 Trial in SMA Type 2 Utilizing Intrathecal Delivery of AVXS-101

AveXis, Inc., a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

Items 51 - 60 of 467  Previous12345678910Next

© 2018 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software